Skip to main content
. 2022 Nov 18;13:977582. doi: 10.3389/fphar.2022.977582

TABLE 3.

Association between different SGLT2 inhibitors and acute pancreatitis occurrence.

Drug A IC(IC025) ROR (95% CI) EBGM(EBGM05)
SGLT-2i 757 2.31 (2.15) 5.03 (4.68, 5.41) 4.97 (4.68)
Canagliflozin 317 2.41 (2.16) 5.37 (4.8, 5.99) 5.32 (4.85)
Dapagliflozin 150 2.26 (1.92) 4.8 (4.09, 5.64) 4.77 (4.17)
Empagliflozin 287 2.25 (2) 4.78 (4.25, 5.37) 4.74 (4.31)
Ertugliflozin 3 1.83 (0.59) 3.58 (1.15, 11.12) 3.57 (1.38)